Autres langues Voyageur Pharmaceuticals Ltd. Toronto S.E.

Actions

VM

CA92916K1057

Produits pharmaceutiques

Temps Différé Toronto S.E. Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^CAD	-.--%		+7,14%	-

18/06	Voyageur Pharmaceuticals évalue trois sites aux États-Unis pour une usine intégrée de produits de contraste à base d'iode et de baryum	CI
10/06	Voyageur Pharmaceuticals Ltd dépose une demande de permis d'exploration pluriannuelle pour l'échantillonnage en vrac et l'étude de faisabilité du projet de barytine Frances Creek	CI

Autres langues

17/07	Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker
23/06	Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
18/06	Voyageur Pharmaceuticals Evaluates Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility
18/06	Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway
10/06	Voyageur Pharmaceuticals Ltd Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support At Frances Creek Barite Project
10/06	Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project
06/06	Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption
05/06	Voyageur Pharmaceuticals Ltd. announced that it has received CAD 5.005278 million in funding
01/05	Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 10 million in funding
01/05	Voyageur Pharmaceuticals Ltd. cancelled the transaction announced on March 24, 2026
24/04	Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 28, 2026
17/04	Voyageur Announces Shares for Debt Settlement and Stock Option Repricing
27/03	Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2025
27/03	Voyageur Pharmaceuticals Ltd. Auditor Raises 'Going Concern' Doubt
24/03	Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 7.5 million in funding
16/03	Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects
05/03	Voyageur Pharmaceuticals : Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant
04/03	Voyageur Pharmaceuticals Ltd. Announces Independent Laboratory Test Results for Its Barium Sulfate Active Pharmaceutical Ingredient
04/03	Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt
23/02	Voyageur Pharmaceuticals Announces Collaboration with Bayer Aktiengesellschaft
23/02	Voyageur Pharmaceuticals Announces Collaboration with Bayer
12/01	Voyageur Pharmaceuticals Ltd. Announces Terminating the Collaboration with Altillion Inc
12/01	Voyageur Pharmaceuticals Ltd. Appoints Brian Mueller as Director of Chemistry, Effective January 12, 2026
12/01	Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology
07/11	Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion